Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge

Antiviral Research

Volumn 95, Issue 3, 2012, Pages 229-236

  Kheiri, Masoumeh Tavassoti ^a   Jamali, Abbas ^a   Shenagari, Mohammad ^b   Hashemi, Hamidreza ^c   Sabahi, Farzaneh ^d   Atyabi, Fatemeh ^e   Saghiri, Reza ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antigenic drift; Nucleoprotein; Virosomal influenza vaccine; Virosome DNA complex

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANZYME B; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIROSOME VACCINE; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GRANZYMES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, VIROSOME; VIRAL CORE PROTEINS;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84864555135     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.07.003     Document Type: Article

References (41)

1. Ada G.L., Jones P.D. The immune response to influenza infection. Curr. Top. Microbiol. Immunol. 1986, 128:1-54.
2. Both G.W., Sleigh M.J., Cox N.J., Kendal A.P. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol. 1983, 48:52-60.
3. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
4. Chiarella P., Fazio V.M., Signori E. Application of electroporation in DNA vaccination protocols. Curr. Gene Ther. 2010, 10:281-286.
5. Correale P., Cusi M.G., Sabatino M., Micheli L., Pozzessere D., Nencini C., Valensin P.E., Petrioli R., Giorgi G., Zurbriggen R., Gluck R., Francini G. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur. J. Cancer 2001, 37:2097-2103.
6. Cusi M.G., Terrosi C., Savellini G.G., Di Genova G., Zurbriggen R., Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 2004, 22:735-739.
7. Daemen T., de Mare A., Bungener L., de Jonge J., Huckriede A., Wilschut J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev. 2005, 57:451-463.
8. de Jonge J., Leenhouts J.M., Holtrop M., Schoen P., Scherrer P., Cullis P.R., Wilschut J., Huckriede A. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem. J. 2007, 405:41-49.
9. Degano P., Sarphie D.F., Bangham C.R. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998, 16:394-398.
10. Dokka S., Toledo D., Shi X., Ye J., Rojanasakul Y. High-efficiency gene transfection of macrophages by lipoplexes. Int. J. Pharm. 2000, 206:97-104.
11. Donnelly J.J., Friedman A., Ulmer J.B., Liu M.A. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997, 15:865-868.
12. Donnelly J.J., Wahren B., Liu M.A. DNA vaccines: progress and challenges. J. Immunol. 2005, 175:633-639.
13. Geeraedts F., Huckriede A. Influenza vaccines: what do we want and how can we get it?. Adv. Exp. Med. Biol. 2011, 780:161-174.
14. Gluck R., Moser C., Metcalfe I.C. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. 2004, 4:1139-1145.
15. Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., Gluck R. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27:4381-4387.
16. Hillaire M.L., Osterhaus A.D., Rimmelzwaan G.F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J. Biomed. Biotechnol. 2011, 939860.
17. Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J. Virol. 2010, 84:12691-12702.
18. Jamali A., Sabahi F., Bamdad T., Hashemi H., Mahboudi F., Kheiri M.T. A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Clin. Vaccine Immunol. 2010, 17:683-687.
19. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., Lalor P., Leamy V., Vahle R., Luke C.J., Rolland A., Kaslow D.C., Smith L.R. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccin. 2007, 3:157-164.
20. Kim Y.C., Jarrahian C., Zehrung D., Mitragotri S., Prausnitz M.R. Delivery systems for intradermal vaccination. Curr. Top. Microbiol. Immunol. 2011, 351:77-112.
21. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 2011, 239:62-84.
22. Matlin K.S., Reggio H., Helenius A., Simons K. Infectious entry pathway of influenza virus in a canine kidney cell line. J. Cell Biol. 1981, 91:601-613.
23. Moser C., Metcalfe I.C., Viret J.F. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines 2003, 2:189-196.
24. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350:896-903.
25. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
26. Nordin J., Mullooly J., Poblete S., Strikas R., Petrucci R., Wei F., Rush B., Safirstein B., Wheeler D., Nichol K.L. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis. 2001, 184:665-670.
27. Palese P. Influenza: old and new threats. Nat. Med. 2004, 10:S82-87.
28. Quan F.S., Compans R.W., Nguyen H.H., Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 2008, 82:1350-1359.
29. Rimmelzwaan G.F., Osterhaus A.D. Influenza vaccines: new developments. Curr. Opin. Pharmacol. 2001, 1:491-496.
30. Schoen P., Chonn A., Cullis P.R., Wilschut J., Scherrer P. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. 1999, 6:823-832.
31. Smirnov Y.A., Gitelman A.K., Govorkova E.A., Lipatov A.S., Kaverin N.V. Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res. 2004, 99:205-208.
32. Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J. 2011, 7:351.
33. Stegmann T., Morselt H.W., Booy F.P., van Breemen J.F., Scherphof G., Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 1987, 6:2651-2659.
34. Stohr K., Kieny M.P., Wood D. Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Nat. Rev. Microbiol. 2006, 4:565-566.
35. Tao P., Luo M., Pan R., Ling D., Zhou S., Tien P., Pan Z. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res. 2009, 81:253-260.
36. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
37. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M.A., Donnelly J.J., Caulfield M.J. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 1998, 72:5648-5653.
38. Webby R.J., Webster R.G. Emergence of influenza A viruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356:1817-1828.
39. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 2007, 44:3672-3681.
40. Yu J.J., Tripp C.S., Russell J.H. Regulation and phenotype of an innate Th1 cell: role of cytokines and the p38 kinase pathway. J. Immunol. 2003, 171:6112-6118.
41. Zamparo E., Little D. Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: a brief review of their utility in the elderly population. J. Prev. Med. Hyg. 2011, 52:116-119.